Explore

Trendline Trendline
Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth

Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth

Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
BioMarin Pharmaceutical Prepares for Earnings Report Amid Slower Revenue Growth

BioMarin Pharmaceutical Prepares for Earnings Report Amid Slower Revenue Growth

BioMarin Pharmaceutical Prepares for Earnings Report Amid Slower Revenue Growth
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance

IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance

IQVIA Exceeds Q1 Sales Estimates, Raises Full-Year Guidance
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data
Trendline Trendline
Schrödinger to Engage Investors at May 2026 Conferences

Schrödinger to Engage Investors at May 2026 Conferences

Schrödinger to Engage Investors at May 2026 Conferences
Trendline Trendline
BioMarin's Q1 Revenue Misses Expectations Amid Amicus Acquisition and Pipeline Developments

BioMarin's Q1 Revenue Misses Expectations Amid Amicus Acquisition and Pipeline Developments

BioMarin's Q1 Revenue Misses Expectations Amid Amicus Acquisition and Pipeline Developments
Trendline Trendline
IQVIA Anticipates Revenue Growth as Earnings Report Approaches

IQVIA Anticipates Revenue Growth as Earnings Report Approaches

IQVIA Anticipates Revenue Growth as Earnings Report Approaches
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates